Specificity of pharmacokinetic modeling of nanomedicines. Issue 10 (October 2021)

• Record Type: Journal Article
• Authors: Lebreton, Vincent; Legeay, Samuel; Saulnier, Patrick; Lagarce, Frederic
• Is Part Of: Drug discovery today. Volume 26:Issue 10(2021)
• Page Start: 2259
• Page End: 2268
• Publication Date: 2021-10
• Subjects: Nanomedicine -- Pharmacokinetics -- Drug evaluation -- Modeling; Drugs -- Design -- Periodicals; Drugs -- Research -- Periodicals; 615.1
• DOI: 10.1016/j.drudis.2021.04.017
• Languages: English
• ISSNs: 1359-6446

Abstract

Highlights: Nanomedicines are intended to optimize the pharmacokinetics of drugs. A proper pharmacokinetic evaluation is essential for drug authorization. Regular pharmacokinetics models are not relevant for nanomedicines. Stability of the nanocarrier in vivo and drug release are key parameters. The carrier itself should be considered as a new compartment in modelling. Abstract: Nanomedicines have been developed for more than four decades to optimize the pharmacokinetics (PK) of drugs, especially absorption, distribution, and stability in vivo. Unfortunately, only a few drug products have reached the market. One reason among others is the lack of proper PK modeling and evaluation, which impedes the optimization of these promising drug delivery systems. In this review, we discuss the specificity of nanomedicines and propose key parameters to take into account for future accurate PK evaluation of nanomedicine. We believe that this could help these innovative drug products to reach to market and change the fate of many diseases.